2023
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia
Stahl M, Giblin G, Liu Y, Winer E, Garcia J, Chen E, Wadleigh M, Ling K, Lindsley R, Shimony S, Copson K, Charles A, DeAngelo D, Stone R, Nohria A, Luskin M. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. Leukemia Research 2023, 132: 107351. PMID: 37451200, DOI: 10.1016/j.leukres.2023.107351.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaInduction chemotherapyVentricular dysfunctionMyeloid leukemiaAllogeneic stem cell transplantationGroup of AML patientsGenetic predictorsBaseline cardiovascular comorbiditiesInclusion criteriaCumulative anthracycline doseStem cell transplantationVentricular ejection fractionConsecutive adult patientsLeft ventricular dysfunctionDana-Farber Cancer InstituteMyeloid mutationsAllo-SCTAnthracycline dosePost-remissionAML patientsCell transplantationEchocardiographic assessmentEjection fractionPrimary endpointJAK2 mutation
2018
Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines
Toro-Salazar OH, Lee JH, Zellars KN, Perreault PE, Mason KC, Wang Z, Hor KN, Gillan E, Zeiss CJ, Gatti DM, Davey BT, Kutty S, Liang BT, Spinale FG. Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines. Cardio-Oncology 2018, 4: 4. PMID: 29900007, PMCID: PMC5995570, DOI: 10.1186/s40959-018-0030-5.Peer-Reviewed Original ResearchLow cumulative dosesBiomarker profilesCumulative dosesSerial cardiac magnetic resonance imagingResultsLeft ventricular ejection fractionCardiac magnetic resonance imagingAbnormal strain parametersSerum biomarker profilesAnti-inflammatory markersVentricular ejection fractionPediatric cancer survivorsPediatric cancer patientsFunctional imaging parametersPlasma biomarker profilesMagnetic resonance imagingAnthracycline doseAnthracycline dosesAnthracycline dosingLongitudinal strain magnitudeSubclinical dysfunctionAnthracycline treatmentEjection fractionPediatric patientsCancer survivorsInterleukin-10
2013
Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study.
Yardley D, Krop I, LoRusso P, Robert N, Mayer M, Abidoye O, Lai C, Yoo B, Perez E. Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study. Journal Of Clinical Oncology 2013, 31: 166-166. DOI: 10.1200/jco.2013.31.26_suppl.166.Peer-Reviewed Original ResearchMetastatic breast cancerObjective response rateHER2-positive metastatic breast cancerT-DM1Investigator-assessed objective response rateMedian cumulative anthracycline doseAccess StudyCumulative anthracycline doseCytotoxic agent DM1HER2-directed agentsMost common gradeUS multicenter studyNew safety signalsRate of gradeConventional clinical trialsAnthracycline doseGrade AEsMBC therapyMeasurable diseaseMedian LVEFPrior anthracyclineSecondary endpointsMUGA scanCardiac dysfunctionMulticenter study
2010
Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction.
Isufi I, Barile A, Russell K, Hryniewicz K, Baker J, Medoff E, Jacoby D, Lee F, Foss F, Cooper D, Seropian S. Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction. Blood 2010, 116: 1309. DOI: 10.1182/blood.v116.21.1309.1309.Peer-Reviewed Original ResearchHigher cumulative anthracycline doseCumulative anthracycline doseEngraftment syndromeAnthracycline doseWBC engraftmentPercent of ptsDay 0Pg/ASCT recipientsHD-CYHigher BNPCardiac complicationsElevated BNPCardiac dysfunctionIntensity conditioningOne-year non-relapse mortalityAllogeneic stem cell transplant recipientsBrain natriuretic peptide elevationIncidence of ESStem cell transplant recipientsWeight gainAcute cardiac complicationsHistory of HTNMore diagnostic criteriaNatriuretic peptide elevation
2003
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. Journal Of Clinical Oncology 2003, 21: 3249-54. PMID: 12947059, DOI: 10.1200/jco.2003.03.111.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerLiposomal doxorubicinBreast cancerOverall survivalDay 1Median cumulative anthracycline doseLeft ventricular ejection fractionPhase II clinical trialCommon grade 3Cumulative anthracycline doseFrequent nonhematologic toxicitiesPrevious anthracycline exposureHand-foot syndromeMedian overall survivalMedian response durationPhase II studyFront-line therapyVentricular ejection fractionOverall response rateAdjuvant chemotherapyAnthracycline doseAssessable patientsMeasurable diseaseNeutropenic complicationsNonhematologic toxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply